within Pharmacolibrary.Drugs.ATC.N;

model N04BC05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 0.0004,
    adminDuration  = 600,
    adminMass      = 1.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.34,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.172,
    k12             = 94,
    k21             = 94
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N04BC05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Pramipexole is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS). It is approved and used clinically today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Hanset, N, et al., &amp; Labriola, L (2019). Influence of hemodialysis on pramipexole pharmacokinetics: Lessons from two cases and literature review. <i>Clinical nephrology. Case studies</i> 7 11–16. DOI:<a href=\"https://doi.org/10.5414/CNCS109641\">10.5414/CNCS109641</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31008016/\">https://pubmed.ncbi.nlm.nih.gov/31008016</a></p></li><li><p>Chwieduk, CM, &amp; Curran, MP (2010). Pramipexole extended release: in Parkinson&#x27;s disease. <i>CNS drugs</i> 24(4) 327–336. DOI:<a href=\"https://doi.org/10.2165/11204570-000000000-00000\">10.2165/11204570-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20297857/\">https://pubmed.ncbi.nlm.nih.gov/20297857</a></p></li><li><p>Merlino, G, et al., &amp; Gigli, GL (2008). Clinical experience with pramipexole in the treatment of restless legs syndrome. <i>Expert opinion on drug metabolism &amp; toxicology</i> 4(2) 225–235. DOI:<a href=\"https://doi.org/10.1517/17425255.4.2.225\">10.1517/17425255.4.2.225</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18248314/\">https://pubmed.ncbi.nlm.nih.gov/18248314</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N04BC05;
